Anti-misuse microparticulate oral pharmaceutical form

• US 8,445,023 B2
• Filed: 12/15/2009
• Issued: 05/21/2013
• Est. Priority Date: 11/10/2005
• Status: Expired due to Fees

• Current Assignee: Flamel Ireland, Ltd.
• Original Assignee: Flamel Technologies SA (Avadel Pharmaceuticals Plc)
• Inventors: Guimberteau, Florence, Dargelas, Frederic
• Primary Examiner(s): DICKINSON, PAUL W
• Application Number:
  US12/638,739
• Publication Number:
  US 20100092553A1
• Time in Patent Office: 1,253 Days
• Field of Search: None
• US Class Current: 424/490
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 47/44 Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14
• CPC Class Codes: A61K 9/2031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
• CPC Class Codes: A61K 9/205 Polysaccharides, e.g. alginate, gums; Cyclodextrin
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61K 9/5021 Organic macromolecular compounds
• CPC Class Codes: A61K 9/5026 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/5047 Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain.

The object of the present invention is to prevent solid oral drugs from being misappropriated for any use other than the therapeutic use(s) officially approved by the competent public health authorities. In other words, the object is to avoid the voluntary or involuntary misuse of solid oral drugs.

The invention relates to a solid oral pharmaceutical form which is characterized in that it contains anti-misuse means, in that at least part of the AP it comprises is contained in coated microparticles for modified release of the AP, and in that the coated microparticles of AP have a coating layer (Ra) which assures the modified release of the AP and simultaneously imparts crushing resistance to the coated microparticles of AP so as to avoid misuse.

Claims

1. A method of preparing a pharmaceutical formulation for combating the misuse of active principle (AP), the method comprising:

providing inert cores;

coating the inert cores with at least one layer comprising the active principle;

coating the at least one layer comprising the active principle with at least one coating layer (Ra) to create modified release coated microparticles resistant to crushing;

wherein said at least one coating layer (Ra) represents a fraction by weight (Tp) greater than 30%, expressed in % by dry weight, based on the total weight of the coated microparticles,

whereby said at least one coating layer (Ra) comprises;

at least one film-forming (co)polymer (A1) insoluble in the gastrointestinal juices present in a proportion of 60% to 90% by weight on a dry basis, relative to the total mass of the coating composition;

at least one (co)polymer soluble in the gastrointestinal juices (A2) present in a proportion of 5% to 40% by weight on a dry basis, relative to the total mass of the coating composition; and

at least one plasticizer (A3) present in a proportion of 1% to 30% by weight on a dry basis, relative to the total mass of the coating composition; and

wherein said formulation further comprises at least one viscosifier (Vb) whereby said formulation further comprises at least one AP sequestering agent Q, whereby a complex with the AP is formed in solution.

2. The method of claim 1, whereby said at least one film-forming (co)polymer (A1) is selected from the group consisting of:

water-insoluble cellulose derivatives, ethyl cellulose, cellulose acetate, acrylic polymers, copolymers of (meth)acrylic acid alkyl ester, copolymers of acrylic and methacrylic acid esters carrying at least one quaternary ammonium group, copolymers of alkyl (meth)acrylate and trimethylammonioethyl methacrylate chloride), polyvinyl acetates, and mixtures thereof;

whereby said at least one (co)polymer soluble in the gastrointestinal juices (A2) is selected from the group consisting of;

nitrogen-containing (co)polymers, polyacrylamides, poly-N-vinylamides, polyvinylpyrrolidones (PVP), poly-N-vinyllactams, water-soluble cellulose derivatives, polyvinyl alcohols (PVA), polyalkylene oxides, polyethylene oxides (PEO), polyethylene glycols (PEG), and mixtures thereof;

whereby said at least one plasticizer (A3) is selected from the group consisting of;

cetyl alcohol esters, glycerol, glycerol esters, acetylated glycerides, glycerol monostearate, glyceryl triacetate, glycerol tributyrate, phthalates, dibutyl phthalate, diethyl phthalate, dimethyl phthalate, dioctyl phthalate, citrates, acetyl tributyl citrate, acetyl triethyl citrate, tributyl citrate, triethyl citrate, sebacates, diethyl sebacate, dibutyl sebacate, adipates, azelates, benzoates, vegetable oils, fumarates, diethyl fumarate, malates, diethyl malate, oxalates, diethyl oxalate, succinates, dibutyl succinate, butyrates, cetyl alcohol esters, salicylic acid, triacetin, malonates, diethyl malonate, castor oil, and mixtures thereof.

3. The method of claim 1, whereby said at least one coating layer (Ra) further comprises at least one surfactant, lubricant, mineral or organic filler (A4) in the following amount (in % by weight, based on the total weight of the coating):

0≦

A4≦

40.

4. The method of claim 3, whereby said at least one surfactant, lubricant, mineral or organic filler (A4) is selected from the group consisting of:

anionic surfactants, alkali metal, alkaline earth metal salts of fatty acids, stearic acid, oleic acid, non-ionic surfactants, polyethoxylated oils, polyethoxylated hydrogenated castor oil, polyoxyethylene/polyoxypropylene copolymers, polyethoxylated sorbitan esters, polyethoxylated castor oil-based compound, stearates, calcium stearate, magnesium stearate, aluminum stearate, zinc stearates, stearylfumarates, sodium stearylfumarate, glycerol behenates, talcum, colloidal silica, titanium oxide, magnesium oxide, bentonite, microcrystalline cellulose, kaolin, aluminum silicate, and mixtures thereof.

5. The method of claim 1, whereby said coated microparticles have a mean diameter between 100 and 600 μ

m less than or equal to 1000 μ

m.

6. The method of claim 1, whereby said formulation is in the form of a tablet, and whereby said coated microparticles comprise at least one outer coating composed of at least one deformable organic constituent with a melting point of between 40°

C. and 120°

C.

7. The method of claim 6, whereby said at least one outer coating represents from 5 to 50% of the total weight of the said coated microparticles of AP by dry weight.

8. The method of claim 1, whereby said at least one viscosifier (Vb) is soluble in at least one of the following solvents:

water, alcohols, ketones and mixtures thereof.

9. The method of claim 8, whereby said at least one viscosifier (Vb) is selected from the group consisting of:

polyacrylic acids, polyacrylic acids derivatives, polyalkylene glycols, polyethylene glycol, polyalkylene oxides, polyethylene oxides, polyvinylpyrrolidones, gelatins, polysaccharides, sodium alginate, pectins, guars, xanthans, carrageenans, gellans, cellulose derivatives, hydroxypropyl methyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, and mixtures thereof.

10. The method of claim 8, whereby said at least one viscosifier (Vb) is a polyoxyethylene with an average molecular weight of 1 million g/mol to 8 million g/mol.

11. The method of claim 1, whereby at least part of said viscosifier (Vb) is in the form of microparticles that are distinct from the microparticles comprising the AP, and inseparable by sieving from the microparticles of AP.

12. The method of claim 1, whereby said at least one AP sequestering agent Q consists of a salt containing at least one ion that forms a complex with the extracted AP salt in solution.

13. The method of claim 12, whereby said at least one ion is an organic ion with opposite polarity to that of the AP in solution.

14. The method of claim 12, whereby said at least one AP sequestering agent Q comprises a salt selected from the group consisting of:

anionic organic salts, carboxymethyl cellulose, carboxymethyl cellulose derivatives, crosslinked carboxymethyl cellulose, crosslinked carboxymethyl cellulose derivatives, polysaccharides, phosphates, trisilicates, saponified fatty acids, self-emulsifying glyceryl monooleates, polyamino acids, proteins, peptides,

cationic metallic salts, cationic organic salts, cationic polymers, and mixtures thereof.

15. The method of claim 12, whereby said at least one AP sequestering agent Q is a salt that is either a strongly acidic cation exchange resin when the AP is cationic, or a strongly basic anion exchange resin when the AP is anionic.

16. The method of claim 15, wherein said at least one AP sequestering agent Q comprises a styrene/divinylbenzene copolymer.

17. The method of claim 15, wherein said at least one AP sequestering agent Q comprises a sulfonated styrene/divinylbenzene copolymer.

18. The method of claim 15, wherein said at least one AP sequestering agent Q comprises a styrene/divinylbenzene copolymer carrying quaternary ammonium groups.

19. The method of claim 15, wherein said at least one AP sequestering agent Q comprises a crosslinked methacrylic acid/divinylbenzene copolymer or one of its salts.

20. The method of claim 15, wherein said exchange resin comprises a phenolic polyamine.

21. The method of claim 11, whereby at least part of said viscosifier (Vb) is in the form of microparticles that are distinct from the microparticles comprising the AP,

whereby said at least one AP sequestering agent Q is in the form of microparticles that are distinct from the microparticles comprising the AP and

whereby said microparticles of Vb and said microparticles of Q are inseparable by sieving from the microparticles of AP.

22. The method of claim 11, whereby said formulation further comprises at least one excipient in a free state.

23. The method of claim 22, whereby said at least one excipient is selected from the group consisting of:

calcium stearate, glycerol palmitostearate, magnesium oxide, polyalkylene glycols, polyethylene glycols, polyvinyl alcohol, sodium benzoate, stearic acid, maize starch, talcum, colloidal silica, zinc stearate, magnesium stearate, stearylfumarate, and mixtures thereof.

24. The method of claim 1, whereby said formulation further comprises immediate release AP.

25. The method of claim 1, whereby said at least one AP is selected from the group consisting of:

amphetamines, narcotics, anorexigenics, antidepressants, antiepileptics, antiparkinsonism substances, anxiolytics, barbiturates, benzodiazepines, hypnotics, neuroleptics, opioids, psychostimulants, psychotropic substances and mixtures thereof.

26. The method of claim 1, whereby said at least one AP is selected from the group consisting of:

anileridine, acetorphine, acetyl-alpha-methylfentanyl, acetyldihydrocodeine, acetylmethadol, alfentanil, allylprodine, alpha-cetylmethadol, alpha-meprodine, alpha-prodine, alpha-methadol, alpha-methylfentanyl, alpha-methylthiofentanyl, atropine, butorphanol, benzethidine, benzylmorphine, beta-hydroxyfentanyl, beta-hydroxy-methyl-3-fentanyl, beta-cetylmethadol, beta-meprodine, beta-methadol, beta-prodine, bezitramide, buprenorphine, dioxaphetyl butyrate, clonitazene, cyclazocine, cannabis, cetobemidone, codeine, coca, cocaine, codoxime, dezocine, dimenoxadol, dipipanone, desomorphine, dextromoramide, dextropropoxyphene, diampromide, diethylthiambutene, difenoxin, dihydrocodeine, dihydroetorphine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, diphenoxylate, drotebanol, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, ecgonine, ephedrine, etorphine, etoxeridine, fentanyl, furethidine, heroin, hydrocodone, hydromorphinol, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, lofentanil, levomethorphan, levomoramide, levophenacylmorphan, levorphanol, meptazinol, meperidine, metazocine, methadone, methyldesorphine, methyldihydromorphine, methylphenidate, methyl-3-thiofentanyl, methyl-3-fentanyl, metopon, moramide, morpheridine, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, nicocodine, nicodicodine, nicomorphine, noracymethadol, norcodeine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, phenadoxone, phenoperidine, promedol, properidine, propiram, propoxyphene, parafluorofentanyl, pentazocine, pethidine, phenampromide, phenazocine, phenomorphan, pholcodine, piminodine, piritramide, proheptazine, propanolol, racemethorphan, racemoramide, racemorphan, remifentanil, sufentanil, thebacon, thebaine, thiofentanyl, tilidine, trimeperidine, tramadol, their pharmacologically acceptable salts, esters, hydrates, polymorphs and isomers, and mixtures thereof.

27. The method of claim 1, whereby said at least one AP is selected from the group consisting of:

oxycodone hydrochloride, morphine sulfate, oxymorphone hydrochloride, hydromorphone hydrochloride, hydrocodone hydrochloride, tramadol hydrochloride, and mixtures thereof.

28. The method of claim 1, whereby said formulation does not contain an AP antagonist.

29. The method of claim 1, whereby said formulation comprises at least two different populations of coated microparticles of AP, whereby each population of coated microparticles has different release kinetics.

30. The method of claim 1, wherein the inert cores are inert cellulose beads.

31. The method of claim 1, wherein coating the inert cores with at least one layer comprising the active principle is by spray-coating.